Home/Filings/4/0001193125-25-318567
4//SEC Filing

AFEYAN NOUBAR 4

Accession 0001193125-25-318567

CIK 0001682852other

Filed

Dec 14, 7:00 PM ET

Accepted

Dec 15, 9:00 AM ET

Size

12.1 KB

Accession

0001193125-25-318567

Insider Transaction Report

Form 4
Period: 2025-12-11
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-11$10.90/sh+23,853$259,99827,777 total(indirect: By Flagship Pioneering, Inc.)
  • Sale

    Common Stock

    2025-12-11$29.48/sh23,853$703,3063,924 total(indirect: By Flagship Pioneering, Inc.)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-12-1123,8530 total(indirect: By Flagship Pioneering, Inc.)
    Exercise: $10.90Exp: 2026-02-23Common Stock (23,853 underlying)
Holdings
  • Common Stock

    (indirect: By Flagship Ventures Fund IV, L.P.)
    3,880,328
  • Common Stock

    (indirect: By Flagship Ventures Fund IV-Rx, L.P.)
    747,897
  • Common Stock

    2,224,015
Footnotes (5)
  • [F1]On December 11, 2025, Flagship Pioneering, Inc. ("Flagship Pioneering") exercised options to purchase 23,853 shares of the Issuer's Common Stock at $10.90 per share, which options were set to expire on February 23, 2026.
  • [F2]The securities are held directly by Flagship Pioneering. Flagship Pioneering is contractually obligated to transfer and/or remit the proceeds of any sale of shares to Flagship Fund IV, L.P. ("Flagship Fund IV"). The reporting person is the CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
  • [F3]The securities are held directly by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
  • [F4]The securities are held directly by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
  • [F5]The options were fully vested and exercisable.

Documents

1 file

Issuer

Moderna, Inc.

CIK 0001682852

Entity typeother

Related Parties

1
  • filerCIK 0001222012

Filing Metadata

Form type
4
Filed
Dec 14, 7:00 PM ET
Accepted
Dec 15, 9:00 AM ET
Size
12.1 KB